Answers are grounded in this paper and cite their sources.
BACKGROUND: Enuresis (bedwetting) affects up to 20% of five-year-old children and 2% of adults. Although spontaneous remission often occurs, the social, emotional and psychological costs can be great. Desmopressin has been used to treat bedwetting since the 1970s. This is an update of a Cochrane review first published in 2000 and last updated in 2006. OBJECTIVES: To assess the effects of desmopressin on treating nocturnal enuresis in children. SEARCH METHODS: We searched Cochrane Incontinence Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, CINAHL, ClinicalTrials.gov, WHO ICTRP, and handsearching of journals and conference proceedings (searched January 2023) and reference lists of relevant articles. SELECTION CRITERIA: We included randomised or quasi-randomised trials of desmopressin or desmopressin combined with another intervention for treating nocturnal enuresis in children between five and 16 years old. DATA COLLECTION AND ANALYSIS: Three review authors independently extracted data and assessed the risk of bias in the eligible trials. We used standard methodological procedures expected by Cochrane. MAIN RESULTS: = 66%; very low-certainty evidence); or if it may increase the number of children achieving 14 consecutive dry nights at the end of treatment (RR 1.53, 95% CI 1.10 to 2.11; participants = 611; studies = 8; low-certainty evidence). There may be little to no difference in adverse events between desmopressin plus anticholinergics and desmopressin monotherapy (RR 1.51 95% CI 0.73 to 3.09, participants = 187; studies =2; low-certainty evidence). Minor adverse effects were common for desmopressin, including dizziness, headache, mood changes, gastrointestinal discomfort, nasal discomfort, hyponatraemia and one report of a convulsion. AUTHORS' CONCLUSIONS: Desmopressin compared with placebo may increase the number of dry nights per week at the end of treatment in children. Desmopressin therapy may be as effective as alarm therapy at the end of treatment. However, the quality of evidence was assessed as low or very low. Alarm therapy compared to desmopressin may improve the number of children who are dry at follow-up (moderate-certainty evidence).
No takes yet. Share an insight, caveat, or question.
Hahn et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: